Collagen Matrix Rebrands to Regenity Biosciences

Collagen Matrix Inc., a Linden Capital Partners portfolio company, has changed its name to Regenity Biosciences and unveiled a new visual identity and website.
 
For more than 25 years, the company has been transforming bioresorbable materials into regenerative solutions to repair and regenerate tissue and bone for a variety of markets including dental, spine, orthopedic, neurosurgery, ENT and nerve repair. After first getting its start with collagen-based medical devices, the company has since introduced numerous bioresorbable technologies with more than 71 product lines commercially available worldwide.
 
Most recently, Regenity expanded its product portfolio to include versatile bioresorbable polymer technologies via the acquisition of Polyganics, which was the impetus behind the new name and brand direction.
 
“Material transformation is at the core of everything we do and the inspiration behind our new name and rebrand,” said Shawn McCarthy, CEO of Regenity. “We recognize the urgency in the work we do because of how critical it is to patients. Regenity represents our commitment to making a material difference with life-changing products, which support our vision to be the global leader in bioresorbable technologies for tissue and bone repair, as we now treat more than four million patients per year.”
 
Along with the new name and vision, Regenity is accelerating its innovation pipeline, mixing a build-it-now mentality with the development of new technology platforms and materials. The company is delivering the next generation of regenerative devices across an expanding range of clinical applications by introducing new synthetic polymers, and other complementary bioresorbable materials, to an already established product portfolio and world-class collagen capabilities. Regenity now operates in five locations in the U.S. and the Netherlands, employing more than 275 associates worldwide.
 
Regenity will unveil its new name and brand at the Society for Biomaterials Annual Meeting in San Diego, held April 19 – April 22, 2023. The company will also be presenting three abstracts on the topics of osteostimulatory properties and in vivo evaluation of their novel bioactive bone graft substitute and novel in vitro models for studying damaged extracellular matrices. This data was generated through the company’s cell biology lab, which was opened in the spring of 2022. Visit Regenity at Booth #205 to learn more.